To evaluate the effects of pharmacological interventions, including cost-effectiveness, when compared to placebo or between different pharmacological agents in controlling psychotic symptoms and other relevant outcome measures in people suffering from ATPD or brief psychotic disorder (BPD).
This is a protocol.